Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
An update from Hims & Hers Health ( (HIMS) ) is now available.
On May 13, 2025, Hims & Hers Health issued $1 billion in senior unsecured notes, which are equal in payment rights to the company’s existing and future senior unsecured debts but are subordinate to secured debts. These notes, maturing on May 15, 2030, offer conversion options into Class A common stock under specific conditions and include provisions for redemption and repurchase under certain corporate events. Additionally, the company engaged in capped call transactions to mitigate potential stock dilution from note conversions, with a cap price set at $89.95 per share, representing a 75% premium over the stock’s last reported sale price on May 8, 2025.
The most recent analyst rating on (HIMS) stock is a Hold with a $40.00 price target. To see the full list of analyst forecasts on Hims & Hers Health stock, see the HIMS Stock Forecast page.
Spark’s Take on HIMS Stock
According to Spark, TipRanks’ AI Analyst, HIMS is a Outperform.
Hims & Hers Health’s strong financial performance and strategic growth initiatives are offset by potential overvaluation and operational challenges. The stock’s upward momentum is promising, but caution is advised due to technical indicators suggesting overbought conditions and the high P/E ratio. The recent convertible notes offering is a positive indicator of future growth potential.
To see Spark’s full report on HIMS stock, click here.
More about Hims & Hers Health
Average Trading Volume: 36,684,719
Technical Sentiment Signal: Buy
Current Market Cap: $12.36B
For detailed information about HIMS stock, go to TipRanks’ Stock Analysis page.